J. Rafael Sierra
Université Bourgogne Franche-Comté(FR)PTC Therapeutics (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Lung Cancer Treatments and Mutations, Hepatocellular Carcinoma Treatment and Prognosis, PI3K/AKT/mTOR signaling in cancer, Complement system in diseases
Most-Cited Works
- → c-MET as a potential therapeutic target and biomarker in cancer(2011)356 cited
- → Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages(2008)281 cited
- → Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy(2010)227 cited
- → The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells(2014)182 cited
- → MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors(2010)170 cited
- → Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition(2010)106 cited
- Immunophenotypic characteristics of blast crisis of chronic myeloid leukaemia: correlations with clinico-biological features and survival.(1993)
- → Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up(2022)23 cited
- → 312 MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors(2010)18 cited
- → Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab(2020)18 cited